Baupost Group’s Theravance Biopharma TBPH Stock Holding History

Baupost Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,200,021	Closed	-$35.6M	–	25
2024 Q2	$35.6M	Sell	4,200,021 -2,394,105	-36%	-$21.6M	0.98%	20
2024 Q1	$59.1M	Sell	6,594,126 -825,100	-11%	-$7.65M	1.62%	15
2023 Q4	$83.4M	Hold	7,419,226	–	–	1.82%	14
2023 Q3	$64M	Hold	7,419,226	–	–	1.23%	20
2023 Q2	$76.8M	Sell	7,419,226 -3,000,000	-29%	-$33.1M	1.37%	18
2023 Q1	$113M	Sell	10,419,226 -1,000,000	-9%	-$10.6M	1.93%	15
2022 Q4	$128M	Sell	11,419,226 -2,000,000	-15%	-$21M	2.09%	18
2022 Q3	$136M	Hold	13,419,226	–	–	2.35%	15
2022 Q2	$122M	Sell	13,419,226 -224,107	-2%	-$2.07M	1.8%	19
2022 Q1	$130M	Sell	13,643,333 -16,835	-0.1%	-$165K	1.4%	20
2021 Q4	$151M	Hold	13,660,168	–	–	1.49%	21
2021 Q3	$101M	Buy	13,660,168 +3,750,000	+38%	+$41.9M	0.93%	24
2021 Q2	$144M	Buy	9,910,168 +1,175,000	+13%	+$22.1M	1.17%	22
2021 Q1	$178M	Hold	8,735,168	–	–	1.42%	20
2020 Q4	$155M	Hold	8,735,168	–	–	1.43%	21
2020 Q3	$129M	Sell	8,735,168 -574,000	-6%	-$10.8M	1.4%	22
2020 Q2	$195M	Hold	9,309,168	–	–	2.44%	13
2020 Q1	$215M	Hold	9,309,168	–	–	3.18%	12
2019 Q4	$241M	Hold	9,309,168	–	–	2.66%	10
2019 Q3	$181M	Hold	9,309,168	–	–	2.05%	15
2019 Q2	$152M	Hold	9,309,168	–	–	1.38%	21
2019 Q1	$211M	Hold	9,309,168	–	–	1.77%	19
2018 Q4	$238M	Hold	9,309,168	–	–	2.07%	14
2018 Q3	$304M	Hold	9,309,168	–	–	2.33%	12
2018 Q2	$211M	Hold	9,309,168	–	–	1.85%	16
2018 Q1	$226M	Hold	9,309,168	–	–	2.18%	16
2017 Q4	$260M	Hold	9,309,168	–	–	2.57%	14
2017 Q3	$319M	Buy	9,309,168 +35,177	+0.4%	+$1.15M	3.97%	10
2017 Q2	$369M	Hold	9,273,991	–	–	4.22%	9
2017 Q1	$341M	Hold	9,273,991	–	–	4.02%	10
2016 Q4	$296M	Buy	9,273,991 +1,923,000	+26%	+$59.6M	3.85%	9
2016 Q3	$266M	Hold	7,350,991	–	–	3.79%	9
2016 Q2	$167M	Buy	7,350,991 +850,000	+13%	+$18.4M	2.26%	14
2016 Q1	$122M	Buy	6,500,991 +80,963	+1%	+$1.32M	1.77%	12
2015 Q4	$105M	Hold	6,420,028	–	–	1.91%	13
2015 Q3	$70.6M	Hold	6,420,028	–	–	1.18%	20
2015 Q2	$83.6M	Buy	6,420,028 +53,451	+0.8%	+$829K	1.39%	14
2015 Q1	$110M	Buy	6,366,577 +305,349	+5%	+$5.6M	1.86%	13
2014 Q4	$90.4M	Hold	6,061,228	–	–	1.78%	11
2014 Q3	$140M	Hold	6,061,228	–	–	2.43%	10
2014 Q2	$193M	Buy	+6,061,228	New	+$182M	3.15%	7

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baupost Group's TBPH Position: Q3 2024 in Review

Baupost Group sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 4,200,021 shares — an estimated $35.6M sold.

Baupost Group first reported a position in TBPH in Q2 2014 and held it in 41 quarters. The position peaked at $369M in Q2 2017. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

Baupost Group reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
Baupost Group sold 4,200,021 Theravance Biopharma shares in Q3 2024, an estimated $35.6M.
Baupost Group first reported a position in Theravance Biopharma in Q2 2014 and held it in 41 quarters.
Baupost Group's Theravance Biopharma position peaked at $369M in Q2 2017.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Baupost Group's 13F filing for Q3 2024, filed 13 Nov 2024.